Skip to Content

LY19-02

Main Content

Determining the optimal conditioning regimen for patients with primary central nervous system lymphoma undergoing autologous hematopoietic cell transplantation.

Study #: LY19-02

Study Status: Published

Presentation(s)

2020, ASH (Oral)

Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant.

Citation

Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS.

JAMA Oncology. 2021, Jul 01: 7(7): 7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. Epub 2021, May 06. PMCID:PMC8283558.

PubMed

PMID: 33956047

Abstract